The increasing prevalence of listeriosis--what are we missing?
Khatamzas
E
E
Department of Microbiology, John Radcliffe Hospital, Oxford OX3 9DU, UK. elham.khatamzas@imm.ox.ac.uk
Hughes
H
H
Grant
K A
KA
McLauchlin
J
J
Bowler
I C J W
IC
D000368:Aged; D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D004032:Diet; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D008089:Listeria monocytogenes / Q000302:isolation & purification; D008088:Listeriosis / Q000453:epidemiology / Q000209:etiology*; D008297:Male; D015995:Prevalence; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D000658:Amoxicillin